Algert Global LLC Has $5.21 Million Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Algert Global LLC lessened its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 23.9% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 115,679 shares of the company’s stock after selling 36,400 shares during the period. Algert Global LLC’s holdings in Protagonist Therapeutics were worth $5,206,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of the business. Sei Investments Co. lifted its holdings in Protagonist Therapeutics by 12.2% during the 1st quarter. Sei Investments Co. now owns 41,758 shares of the company’s stock worth $1,208,000 after buying an additional 4,529 shares during the period. Russell Investments Group Ltd. acquired a new position in shares of Protagonist Therapeutics in the first quarter worth approximately $35,000. Vanguard Group Inc. boosted its holdings in Protagonist Therapeutics by 1.2% in the first quarter. Vanguard Group Inc. now owns 3,192,971 shares of the company’s stock valued at $92,373,000 after acquiring an additional 39,055 shares during the last quarter. CANADA LIFE ASSURANCE Co increased its position in Protagonist Therapeutics by 74.2% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 9,083 shares of the company’s stock valued at $263,000 after purchasing an additional 3,870 shares during the period. Finally, Lazard Asset Management LLC bought a new position in Protagonist Therapeutics during the 1st quarter worth approximately $69,000. Institutional investors own 98.63% of the company’s stock.

Protagonist Therapeutics Trading Up 11.5 %

NASDAQ PTGX opened at $46.46 on Monday. The company has a market cap of $2.77 billion, a P/E ratio of 17.47 and a beta of 2.17. The company has a fifty day simple moving average of $45.25 and a 200 day simple moving average of $39.34. Protagonist Therapeutics, Inc. has a 12-month low of $16.80 and a 12-month high of $48.89.

Insider Activity

In other Protagonist Therapeutics news, CFO Asif Ali sold 14,203 shares of Protagonist Therapeutics stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $44.49, for a total transaction of $631,891.47. Following the completion of the transaction, the chief financial officer now owns 34,960 shares in the company, valued at approximately $1,555,370.40. The trade was a 28.89 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director William D. Waddill sold 8,000 shares of the stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $45.00, for a total value of $360,000.00. Following the completion of the sale, the director now directly owns 12,000 shares of the company’s stock, valued at approximately $540,000. This trade represents a 40.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 24,109 shares of company stock worth $1,069,999 over the last three months. 5.40% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. Wedbush reiterated an “outperform” rating and set a $58.00 price objective on shares of Protagonist Therapeutics in a research report on Tuesday, November 19th. Truist Financial assumed coverage on Protagonist Therapeutics in a report on Monday, September 9th. They issued a “buy” rating and a $60.00 target price for the company. TD Cowen upgraded Protagonist Therapeutics to a “strong-buy” rating in a report on Wednesday, September 25th. StockNews.com upgraded shares of Protagonist Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Finally, JMP Securities cut their target price on shares of Protagonist Therapeutics from $45.00 to $43.00 and set a “market outperform” rating on the stock in a research note on Wednesday, August 7th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $53.57.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.